These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19104936)

  • 1. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
    Johnston RL; Lutzky J; Chodhry A; Barkin JS
    Dig Dis Sci; 2009 Nov; 54(11):2538-40. PubMed ID: 19104936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
    Minor DR; Chin K; Kashani-Sabet M
    Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: colitis associated with anti-CTLA-4 therapy.
    Gupta A; De Felice KM; Loftus EV; Khanna S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
    Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
    Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
    Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
    Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab-induced colitis in patients with metastatic melanoma.
    De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
    Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
    Klair JS; Girotra M; Hutchins LF; Caradine KD; Aduli F; Garcia-Saenz-de-Sicilia M
    Dig Dis Sci; 2016 Jul; 61(7):2132-9. PubMed ID: 26846115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
    Marthey L; Mateus C; Mussini C; Nachury M; Nancey S; Grange F; Zallot C; Peyrin-Biroulet L; Rahier JF; Bourdier de Beauregard M; Mortier L; Coutzac C; Soularue E; Lanoy E; Kapel N; Planchard D; Chaput N; Robert C; Carbonnel F
    J Crohns Colitis; 2016 Apr; 10(4):395-401. PubMed ID: 26783344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab: a novel treatment for ipilimumab-induced colitis.
    Hsieh AH; Ferman M; Brown MP; Andrews JM
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint Inhibitor-Induced Colitis.
    Bellaguarda E; Hanauer S
    Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
    Beniwal-Patel P; Matkowskyj K; Caldera F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
    Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.